Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
23 Noviembre 2022 - 8:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) announces that, subsequent to the LOI,
Sirona and Wanbang Biopharmaceuticals (“
Wanbang”)
have signed an expanded, international partnership agreement to
collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a
pharmaceutical treatment in both animal and human health. The
agreement adds human health to the partnership as a result of new
licencing opportunities currently in due diligence.
Wanbang (a wholly owned subsidiary of Shanghai
Fosun Pharmaceutical) and Sirona initially signed a licensing
agreement for TFC-039, whereby Wanbang obtained the rights to
develop the compound as a diabetes treatment in China and Sirona
retained the global rights. Sirona has since been in discussions
with animal health companies to advance TFC-039 as a treatment for
diabetes and chronic kidney disease in companion animals. SGLT2
inhibitors provide an opportunity to treat inflicted animals with
an oral medication as opposed to the traditional method of daily
insulin injections. More recently, Sirona has entered into due
diligence with a large pharmaceutical company with a regional
interest in developing the compound for human diabetes.
Together, Sirona and Wanbang share extensive
knowledge and scientific results of TFC-039. Partnering will
significantly increase the speed to third-party partnerships and
commercialization. The shared data spans over 12 years of research
and development, and includes in vitro and in vivo preclinical
work, multiple clinical studies, advanced manufacturing process
development and the ability to commercially manufacture
TFC-039.
“We have a long-standing relationship with
Wanbang and are excited to combine our two companies’ expertise to
license TFC-039. Wanbang has invested millions of dollars into the
clinical stage research and development of the manufacturing
processes for TFC-039. These pieces of data are critical to large
organizations and will greatly increase the opportunities to move
forward. The probability of a successful licensing agreement has
been made much stronger by leveraging our alliance with Wanbang.”
said Dr. Howard Verrico, CEO. “We have had a successful year
building Sirona’s pipeline, with positive movement on all projects
and we’re looking forward to continuing this success with our SGLT2
inhibitor as well as our antiviral and anti-aging projects in
2023.”
About Wanbang Biopharmaceuticals and
Fosun Pharmaceuticals
Wanbang Biopharmaceuticals develops,
manufactures, and markets drugs with indications for chronic
disease treatment, antibiotics, and other endocrine diseases in
China. Founded in 1981, the company is headquartered in Xuzhou,
China, and is a subsidiary of Shanghai Fosun Pharmaceutical Group.
Fosun is a leader in the pharmaceutical industry and is regarded as
one of the top five domestic pharmaceutical companies in China. For
more information on Fosun and Wanbang, please visit
www.fosunpharma.com/en.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
located in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information regarding this press
release, please contact:
Jonathan WilliamsManaging DirectorMomentum PRPhone:
1.450.332.6939Email:
jwilliams@momentumpr.com
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem’s forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem’s business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
BMO Short Term Bond Inde... (TSX:ZSB)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
BMO Short Term Bond Inde... (TSX:ZSB)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024